Company Number: 13857099

Analysis Date: 2025-07-29 15:43 UTC

1. Market Position
   Etheridge Clinical Research Ltd operates within the niche segment of professional, scientific, and technical activities as classified under SIC code 74909, focusing on clinical research services. As a relatively new entrant (incorporated in 2022) and a micro to small-sized private limited company, it appears to be establishing itself primarily in the UK market, specifically Liverpool. The company currently serves a specialized market likely comprising pharmaceutical, biotech, or healthcare clients requiring clinical research support, which is a growing sector driven by innovation and regulatory demands.

2. Strategic Assets

• Strong Financial Foundation and Growth: The company’s net assets have more than doubled from £27.6k in 2023 to £59.7k in 2024, reflecting improved working capital and operational scale. This is primarily driven by a significant increase in debtors (£28.9k to £144.3k), indicating expanding client engagements and revenue recognition on services rendered.
• Founder-led Expertise and Control: Mr. Alexander Luke Etheridge, the director and significant shareholder (75-100% ownership), brings direct clinical research experience (Clinical Research Associate), aligning leadership with domain expertise and enabling agile decision-making.
• Low Fixed Asset Base with High Liquidity: The company maintains low fixed tangible assets (£328) but strong current assets (£168k), including cash (£23.8k), suggesting operational flexibility and minimal capital expenditure requirements typical for service-focused firms.
• Strong Shareholder Funding and Loan Support: The director has extended substantial unsecured loans to the company (£90.6k outstanding), indicating committed insider financial backing to support growth and liquidity.

3. Growth Opportunities

• Scaling Client Base and Service Offering: The significant increase in debtors suggests the company is winning more contracts or extending credit terms to clients. Formalizing and expanding service contracts, perhaps targeting mid to large pharmaceutical companies or CRO collaborations, can drive sustainable revenue growth.
• Geographic Expansion and Regulatory Expertise: Leveraging Liverpool as a base, the company can target broader UK and European markets, especially as clinical research regulations evolve post-Brexit, offering compliance and consultancy services alongside research activities.
• Technology Integration: Investment in digital tools for trial management, data analytics, or patient recruitment could enhance service differentiation and operational efficiency.
• Partnerships and Alliances: Forming strategic alliances with larger CROs or academic institutions could offer access to larger projects and diversified revenue streams.

4. Strategic Risks

• Client Concentration and Credit Risk: The disproportionate increase in debtors without a corresponding increase in cash suggests potential concentration risk or slower collections, which could strain liquidity if clients delay payments.
• Resource Constraints and Single-Employee Operation: With only one employee (the director) reported, scaling operations may be limited without additional skilled hires, potentially impacting delivery capacity and client satisfaction.
• Financial Dependence on Insider Funding: Reliance on director loans to fund operations, while positive in the short term, may pose risks if external financing is not secured as the company grows.
• Regulatory and Competitive Pressures: The clinical research industry is highly regulated and competitive, with established CROs dominating. As a small player, the company must continuously invest in compliance and quality to maintain credibility and avoid costly penalties.